October 3, 2019 11:13 AM EDTUpdated 11:45 AM
Financing
Startups

Aeov­ian Phar­ma­ceu­ti­cals brings in $37 mil­lion in mTOR play

Jason Mast

Editor

San Fran­cis­co-based Aeov­ian Phar­ma­ceu­ti­cals has banked $37 mil­lion in Se­ries A fi­nanc­ing to launch its mTORC1 in­hibitor in­to a proof-of-con­cept for what the com­pa­ny says …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times